East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg. Aurobindo Pharma’s Chlorpromazine Hydrochloride Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Chlorpromazine Hydrochloride Tablets manufactured by Upsher-Smith Laboratories, LLC.

Chlorpromazine Hydrochloride Tablets are indicated:

• For the management of manifestations of psychotic disorders.
• For the treatment of schizophrenia.
• To control nausea and vomiting.
• For relief of restlessness and apprehension before surgery.
• For acute intermittent porphyria.
• As an adjunct in the treatment of tetanus.
• To control the manifestations of the manic type of manic-depressive illness.
• For relief of intractable hiccups.
• For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance.